Revolutionary T-Cell Therapy Brings New Hope to Leukemia Patients

December 7, 2014 5:51 PM

12 0

In a recent press release, Novartis, a Swiss multinational drug producer, that 92 percent of the patients with acute lymphoblastic leukemia (ALL) experienced complete remissions after undergoing the CTL09 therapy. Also, about 70 to 75 percent of the patients survived a 6-month period without further therapy and no disease comebacks.

Novartis’ CTL09 therapy is a medical technology that uses Chimeric Antigen Receptors (CARs) to reprogram patients’ T cells to start fighting cancer cells that contain CD19 proteins. The reprogrammed T cells also known as CTL09 enter the circulatory system, multiply and hunt down CD19 cells. Novartis...

Read more

To category page